1,647 results on '"Reiter, Andreas"'
Search Results
2. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
3. A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis
4. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
5. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
6. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort
7. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
8. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
9. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
10. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
11. How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions
12. Managing multi-tiered innovation ecosystems
13. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group
14. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
15. Myeloische/lymphatische Neoplasien mit Eosinophilie und Tyrosinkinase-Fusionsgenen
16. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
17. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
18. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
19. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
20. Idiopathic hypereosinophilic syndrome—diagnosis and treatment
21. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis
22. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
23. Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases
24. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
25. Avapritinib for advanced systemic mastocytosis
26. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
27. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
28. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
29. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
30. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
31. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
32. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
33. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
34. Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis
35. Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosis
36. Digital Transformer’s Dilemma: Innovate Twice to Survive
37. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
38. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
39. Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies
40. Dual-porosity approach: heat transfer and heat storage processes in porous media
41. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry
42. Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5
43. Mastocytosis
44. Tyrosine Kinase Inhibitors in Systemic Mastocytosis
45. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
46. Statistical Treatment of Beam Position Monitor Data
47. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis
48. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
49. Investigation of opening eye defects and effects of different ripening profiles on eye structure in semi-hard cheese using X-ray micro-computed tomography
50. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.